Cargando…
The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs). Moderate to severe irAEs are typically trea...
Autores principales: | Bruera, Sebastian, Suarez-Almazor, Maria E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445222/ https://www.ncbi.nlm.nih.gov/pubmed/36081549 http://dx.doi.org/10.3389/fonc.2022.928390 |
Ejemplares similares
-
Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy
por: Abdel-Wahab, Noha, et al.
Publicado: (2019) -
COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review
por: Ruiz, Juan I., et al.
Publicado: (2023) -
Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
por: Riveiro-Barciela, Mar, et al.
Publicado: (2023) -
Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis
por: Chen, Kefan, et al.
Publicado: (2023) -
Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)